Abstract:Background : The 3C-like proteases (3CL pro s) are cysteine-rich homodimeric proteins and can be covalently modified by numerous natural and synthetic compounds, which in turn, block the proteolytic activity or the formation of enzymatically active dimeric forms. Although herbal medicines have been widely used to treat COVID-19, identification of the key herbal constituents that can covalently modify the 3CL pro s in β-coronaviruses (CoVs) remains a big challenge. Aims : To construct a comprehensive approach for efficient discovering the covalent SARS-CoV-2 3CL pro inhibitors from herbal medicines. To decipher the key anti-SARS-CoV-2 3CL pro constituents in Ginkgo biloba extract 50 (GBE50) and to study their anti-SARS-CoV-2 3CL pro mechanisms. Methods : SARS-CoV-2 3CL pro inhibition assay including time-dependent inhibition assays and inactivation kinetic analyses were conducted using a fluorescence-based biochemical assay. The constituents in GBE50 were analyzed by UHPLC-Q-Exactive Orbitrap HRMS. The peptides modified by herbal constituents were characterized by using nanoLC-MS/MS. Results : Following testing the anti-SARS-CoV-2 3CL pro effects of 104 herbal medicines, it was found that Ginkgo biloba extract 50 (GBE50) potently inhibited SARS-CoV-2 3CL pro in dose- and time-dependent manners. A total of 38 constituents were identified from GBE50 by UHPLC-Q-Exactive Orbitrap HRMS, while 26 peptides modified by 18 constituents were identified by chemoproteomic profiling. The anti-SARS-CoV-2 3CL pro effects of 18 identified covalent inhibitors were then validated by performing time-dependent inhibition assays. The results clearly demonstrated that most tested constituents showed time-dependent inhibition on SARS-CoV-2 3CL pro , while gallocatechin and sciadopitysin displayed the most potent anti-SARS-CoV-2 3CL pro effects. Conclusion : Collectively, GBE50 and some constituents in this herbal product could strongly inhibit SARS-CoV-2 3CL pro in dose- and time-dependent manner. Gallocatechin and sciadopitysin were identified as potent SARS-CoV-2 3CL pro inhibitors, which offers promising lead compounds for the development of novel anti-SARS-CoV-2 drugs.

Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases

Natural Product Compounds in Alpinia officinarum and Ginger are Potent SARS-CoV-2 Papain-like Protease Inhibitors

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation

Discovery and Characterization of the Covalent SARS-CoV-2 3clpro Inhibitors from Ginkgo Biloba Extract Via Integrating Chemoproteomic and Biochemical Approaches

Discovery of Chebulagic Acid and Punicalagin As Novel Allosteric Inhibitors of SARS-CoV-2 3Clpro.

Discovery and characterization of the covalent SARS-CoV-2 3CL pro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches

Naphthalen-1-ylethanamine-containing small molecule inhibitors of the papain-like protease of SARS-CoV-2

Design, Synthesis and Biological Evaluation of Novel 3C-Like Protease Inhibitors As Lead Compounds Against SARS-CoV-2.

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL<SUP>pro</SUP> from <i>Ginkgo</i> <i>biloba</i> leaves <i>via</i> large-scale screening

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease

Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19

Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2

The natural polyphenol fortunellin and its structural analogs are inhibitors of the SARS-CoV-2 main proteinase dimerization, as revealed by molecular simulation studies

Design and synthesis of isatin derivatives as effective SARS‐CoV‐2 3CL protease inhibitors

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease